Hideyuki Nakazawa
Overview
Explore the profile of Hideyuki Nakazawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Itonaga H, Miyazaki Y, Kondo T, Shimazu Y, Aoki J, Kurosawa S, et al.
Am J Hematol
. 2025 Feb;
PMID: 39932123
No abstract available.
2.
Shinohara A, Shindo M, Nakano N, Sakaida E, Uchida N, Fukushima K, et al.
Eur J Haematol
. 2025 Jan;
PMID: 39834012
Fludarabine and myeloablative busulfan (FluBu4) in allogeneic hematopoietic stem cell transplantation (HSCT) for older people have not been adequately examined. This retrospective study analyzed data from a large-scale, nationwide database...
3.
Fujioka M, Itonaga H, Nakazawa H, Nishida T, Kataoka K, Ikeda T, et al.
Transplant Cell Ther
. 2024 Oct;
31(1):18.e1-18.e12.
PMID: 39374663
The fludarabine/intravenous busulfan 12.8 mg/kg (FB4) regimen is an effective conditioning regimen in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS); however, limited data is available on the prognostic...
4.
Nishikubo M, Shimomura Y, Nakaya Y, Shinohara A, Uchida N, Takayama N, et al.
Bone Marrow Transplant
. 2024 Sep;
59(12):1735-1743.
PMID: 39322651
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for relapsed or refractory non-Hodgkin lymphoma (R/R NHL). Allo-HSCT using post-transplant cyclophosphamide (PTCY-haplo) and umbilical cord blood transplantation (uCBT) are...
5.
Mizuno Y, Kawakami T, Higano D, Miyairi S, Asakura A, Kawakami F, et al.
Haematologica
. 2024 May;
109(9):3067-3070.
PMID: 38813714
No abstract available.
6.
Nishimori H, Nakazawa H, Tamura S, Uchida T, Usuki K, Szamosi J, et al.
Acta Haematol
. 2024 Apr;
148(1):22-35.
PMID: 38615657
Introduction: Pegcetacoplan, the first approved proximal complement C3 inhibitor, showed superiority to eculizumab in improving hemoglobin levels and clinical outcomes in the phase 3 PEGASUS study in patients with paroxysmal...
7.
Kuriyama K, Fuji S, Ito A, Doki N, Katayama Y, Ohigashi H, et al.
Transplant Cell Ther
. 2024 Feb;
30(5):514.e1-514.e13.
PMID: 38373522
The purine analog fludarabine (Flu) plays a central role in reduced-intensity conditioning and myeloablative reduced-toxicity conditioning regimens because of limited nonhematologic toxicities. Few reports assess the impact of different dose...
8.
Kato K, Sugio T, Ikeda T, Yoshitsugu K, Miyazaki K, Suzumiya J, et al.
Bone Marrow Transplant
. 2023 Dec;
59(3):306-314.
PMID: 38102209
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a currative treatment modality for diffuse large B-cell lymphoma (DLBCL) because of the intrinsic graft-versus-lymphoma effect. However, limited information is available regarding which...
9.
Yanagisawa R, Yamanaka M, Kawakami F, Nakazawa H
Allergol Int
. 2023 Oct;
73(1):184-186.
PMID: 37802754
No abstract available.
10.
Watanabe M, Kanda J, Fukuda T, Uchida N, Ikegame K, Kataoka K, et al.
Br J Haematol
. 2023 Aug;
203(3):446-459.
PMID: 37614023
The graft-versus-lymphoma (GVL) effect and its association with acute and chronic GVHD (aGVHD, cGVHD) has not been comprehensively elucidated. We retrospectively analysed 2204 Japanese patients with non-Hodgkin lymphomas (NHLs; indolent...